Mogelijk gemaakt door 
Translate
Translate
January 2025 – The Big News!
Big things are happening at BNCM! The company has officially joined forces with DELEX Group, marking the start of a thrilling new chapter in its journey. The management transfer process is set to be completed by March 2025, and it promises to supercharge BNCM's growth under the leadership of DELEX. Here’s a closer look at the bold moves and exciting plans ahead:
The transition to DELEX Group’s management begins this month, and it’s all systems go. Throughout this shift, the talented BNCM team will continue to play a vital role, ensuring smooth operations and a seamless handover of responsibilities as the new leadership steps in.
With DELEX now holding a dominant 59.25% majority stake, BNCM is poised for incredible growth. The remaining shares (15.75% for BNCM and 25% for the public and other shareholders) will keep the company’s future in diverse and dynamic hands. The finalized share structure will be unveiled in the upcoming Q4 report.
DELEX is bringing in a team that’s already proven its success. The new management team is packed with seasoned professionals who have led DELEX Pharma to new heights for over 15 years. These top-tier executives will now drive BNCM’s future success.
Key Members of the Team:
Hatadi Supaat has agreed to remain as CEO for BNCM for the next 6 months and as Corporate Advisor for several months to ensure a smooth transition and focus on the Investor Relations (IR) campaign for BNCM which he strongly believes needs to be done aggressively with an experienced IR team.
BNCM is about to take the investment world by storm. The upcoming IR campaign is set to break new ground, utilizing cutting-edge digital marketing, AI technology, and innovative branding strategies. This campaign will boost BNCM’s market visibility, attract investors, enhance stakeholder confidence, and ultimately drive shareholder returns to new heights.
DELEX’s aggressive expansion strategy is nothing short of groundbreaking. Over the next five years, they’re targeting huge growth across all facets of the business:
Out with the old, in with the new! BNCM will officially apply to change its name to DELEX, alongside an updated ticker symbol, reflecting the bold new direction of the company. Expect big things in Q1 2025!
DELEX is taking things to the next level by filing a Regulation A application with the SEC starting in March 2025. This move will provide even more opportunities for expansion and growth as DELEX continues to push boundaries.
DELEX has its sights set on an OTCQB listing, with a goal to eventually move up to OTCQX and potentially NASDAQ. As the company continues to meet the necessary standards, expect DELEX to make waves in the market!
About DELEX Healthcare Group, Inc. (DELEX)
DELEX is on a mission to revolutionize the pharmaceutical and healthcare industry. As a Delaware-registered company, DELEX partners with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc., bringing high-quality products to market. With a focus on innovation, regulatory excellence, and customer service, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence.
For more information, visit - https://bncm.net/
Disclaimer: The information presented in this article is for informational purposes only and does not constitute financial, investment, or business advice. DELEX future plans, projections, and growth strategies are subject to various risks and uncertainties, and actual results may differ significantly. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. DELEX is not responsible for any financial or investment outcomes resulting from the use of this information.
